Is Granules India a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Granules India Ltd is a average quality company .

Is Granules India undervalued or overvalued?

The key valuation ratios of Granules India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Granules India share price return in the past 10 years?

Granules India Ltd share price has appreciated 24.6% annually (CAGR) over the past ten years.

Is Granules India a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Granules India Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Granules India Ltd - Stock Valuation and Financial Performance

Name: Granules India
Brand: Granules India

BSE: 532482 | NSE: GRANULES | Pharmaceuticals & Drugs | Small Cap

Place order

Granules India Share Price

₹565.25 14.40 2.61%
as on 26-Jul'24 16:01

10 Year X-Ray of Granules India:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	15.5%	13.7%	11.9%	8.3%	7.4%	13.3%	20.2%	12.3%	14.8%	12.6%	-
Value Creation Index ⓘ	0.1	0.0	-0.2	-0.4	-0.5	-0.1	0.5	-0.1	0.1	-0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1,215	1,328	1,349	1,647	2,098	2,310	3,135	3,238	3,931	3,755	3,755
Sales YoY Gr.	-	9.3%	1.6%	22%	27.4%	10.1%	35.7%	3.3%	21.4%	-4.5%	-
Adj EPS ⓘ	4.7	5.6	6.4	5.3	6	12.7	22.6	15.9	20.9	18.1	18
YoY Gr.	-	19%	14.7%	-17.1%	13.4%	111%	77.9%	-29.5%	31.1%	-13.1%	-
BVPS (₹) ⓘ	20.8	29.3	38.6	50.1	55.7	70.9	86.9	101.6	111	127.8	127.8
Adj Net Profit ⓘ	95.6	121	146	135	153	322	559	394	505	439	436
Cash Flow from Ops. ⓘ	135	144	190	24	227	495	375	280	664	317	-
Debt/CF from Ops. ⓘ	3.1	4.5	3.5	40.8	4.4	1.8	2.2	3.7	1.4	3.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	13.4%	12.3%	6.2%	-4.5%
Adj EPS ⓘ	16.2%	24.7%	-7.1%	-13.1%
BVPSⓘ	22.4%	18.1%	13.7%	15.2%
Share Price	24.6%	45.9%	15.7%	75.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	24.8	22.1	18.9	12.4	11.3	19.9	28.1	16.8	19.3	15.1	14.1
Op. Profit Mgn % ⓘ	17.4	20.3	22.3	17.8	15.9	21.4	27.8	20.2	21.5	21.5	21.3
Net Profit Mgn % ⓘ	7.9	9.1	10.8	8.2	7.3	14	17.8	12.2	12.8	11.7	11.6
Debt to Equity ⓘ	1	1	0.7	0.8	0.7	0.5	0.4	0.4	0.3	0.3	0
Working Cap Days ⓘ	110	168	241	278	237	195	169	211	198	228	120
Cash Conv. Cycle ⓘ	34	78	115	117	114	98	74	110	95	118	38

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 14.10%

Sales growth has been subdued in last 3 years 6.20%

Net Profit has been subdued in last 3 years -7.06%

Sales growth is not so good in last 4 quarters at -4.51%

Latest Financials - Granules India Ltd.

	Standalone	Consolidated
TTM EPS (₹)	18	16.7
TTM Sales (₹ Cr.)	3,755	4,506
BVPS (₹.) ⓘ	127.8	132.3
Reserves (₹ Cr.) ⓘ	3,073	3,183
P/BV ⓘ	4.41	4.26
PE ⓘ	31.33	33.69

From the Market
52 Week Low / High (₹)	287.55 / 566.45
All Time Low / High (₹)	1.57 / 555.05
Market Cap (₹ Cr.)	13,656
Equity (₹ Cr.)	24.2
Face Value (₹)	1
Industry PE ⓘ	45.5

Management X-Ray of Granules India:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

6.92

10.59

4.03

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Granules India

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Granules India

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1,215	1,328	1,349	1,647	2,098	2,310	3,135	3,238	3,931	3,755
Operating Expenses ⓘ	1,004	1,058	1,054	1,353	1,766	1,816	2,274	2,594	3,096	2,954
Manufacturing Costs	82	99	122	152	173	195	233	291	294	364
Material Costs	707	730	659	903	1,250	1,222	1,510	1,758	2,161	1,907
Employee Cost	89	106	126	148	167	193	234	248	278	333
Other Costs ⓘ	125	123	148	150	175	206	296	298	362	350
Operating Profit ⓘ	211	270	296	294	332	494	861	644	835	801
Operating Profit Margin (%)	17.4%	20.3%	21.9%	17.8%	15.8%	21.4%	27.5%	19.9%	21.2%	21.3%
Other Income ⓘ	1	7	15	24	28	26	14	18	13	6
Interest ⓘ	31	37	32	33	28	27	24	16	39	72
Depreciation ⓘ	50	58	71	76	91	102	118	126	146	144
Exceptional Items ⓘ	0	0	0	0	0	161	0	0	0	0
Profit Before Tax ⓘ	132	181	207	208	242	553	733	520	664	591
Tax ⓘ	37	60	64	69	80	109	180	133	165	155
Profit After Tax	95	121	143	139	162	444	553	387	499	436
PAT Margin (%)	7.8%	9.1%	10.6%	8.5%	7.7%	19.2%	17.6%	11.9%	12.7%	11.6%
Adjusted EPS (₹)	4.7	5.6	6.3	5.5	6.4	17.5	22.3	15.6	20.6	18.0
Dividend Payout Ratio (%)	11%	12%	14%	18%	16%	6%	7%	10%	7%	8%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	425	636	882	1,273	1,416	1,803	2,152	2,518	2,686	3,097
Share Capital ⓘ	20	22	23	25	25	25	25	25	24	24
Reserves ⓘ	405	614	859	1,247	1,391	1,777	2,128	2,494	2,662	3,073
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	358	577	598	958	933	793	743	954	812	954
Long Term Debt	243	184	124	433	479	421	334	234	149	50
Short Term Debt	115	393	474	525	454	372	409	720	663	904
Trade Payables	183	177	210	261	277	323	508	607	744	655
Others Liabilities ⓘ	141	178	165	147	198	228	280	294	261	300
Total Liabilities ⓘ	1,107	1,568	1,855	2,639	2,824	3,146	3,683	4,373	4,503	5,006
Fixed Assets
Gross Block	726	785	937	1,066	1,195	1,523	1,693	1,949	2,201	2,312
Accumulated Depreciation	204	261	332	405	495	596	708	778	871	989
Net Fixed Assetsⓘ	522	523	606	660	700	927	985	1,171	1,330	1,324
CWIP ⓘ	18	35	132	286	333	130	164	211	63	53
Investmentsⓘ	72	89	75	75	506	445	592	597	677	941
Inventories	179	210	238	227	314	344	462	591	593	579
Trade Receivables	194	444	468	693	704	627	1,014	1,210	1,372	1,633
Cash Equivalents	52	111	39	97	62	272	241	355	203	228
Others Assetsⓘ	68	155	297	600	204	401	225	238	265	248
Total Assets ⓘ	1,107	1,568	1,855	2,639	2,824	3,146	3,683	4,373	4,503	5,006

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	135	144	190	24	227	495	375	280	664	317
PBT ⓘ	132	181	207	208	242	553	733	520	664	591
Adjustment ⓘ	81	91	95	92	122	-54	154	137	178	229
Changes in Working Capital ⓘ	-47	-80	-53	-223	-50	115	-326	-234	-1	-347
Tax Paid ⓘ	-31	-48	-59	-53	-87	-120	-186	-143	-177	-157
Cash Flow From Investing Activity ⓘ	-130	-171	-300	-495	-243	-165	-233	-318	-96	-303
Capex	-102	-100	-184	-275	-188	-119	-222	-324	-212	-119
Net Investments	0	0	-1	0	2	20	-14	0	200	16
Others ⓘ	-28	-72	-115	-220	-57	-66	3	5	-84	-200
Cash Flow From Financing Activityⓘ	25	86	36	529	-17	-212	-296	151	-519	26
Net Proceeds from Shares ⓘ	1	106	83	293	1	0	4	3	3	3
Net Proceeds from Borrowing ⓘ	39	-55	-66	250	102	-60	-102	-95	-93	-102
Interest Paid ⓘ	-31	-37	-32	-31	-28	-27	-24	-17	-37	-72
Dividend Paid ⓘ	-8	-23	-22	-29	-31	-31	-25	-37	-19	-36
Others ⓘ	24	96	73	46	-62	-95	-150	298	-374	233
Net Cash Flow ⓘ	30	58	-73	58	-33	118	-154	113	48	40

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	24.88	22.8	18.82	12.92	12.04	27.59	27.95	16.55	19.17	15.08
ROCE (%)	21.66	20.36	16.79	12.71	11.56	22.67	26.53	16.29	19.55	17.06
Asset Turnover Ratio	1.27	1.01	0.8	0.74	0.77	0.78	0.93	0.8	0.89	0.79
PAT to CFO Conversion(x)	1.42	1.19	1.33	0.17	1.4	1.11	0.68	0.72	1.33	0.73
Working Capital Days
Receivable Days	46	86	121	128	120	105	94	125	120	146
Inventory Days	44	53	59	51	47	52	46	59	55	57
Payable Days	80	90	107	95	78	90	100	116	114	134

Granules India Ltd Stock News

Granules India Ltd FAQs

What is the share price of Granules India?

Company share prices are keep on changing according to the market conditions. The closing price of Granules India on 26-Jul-2024 16:01 is ₹565.2.

What is the market cap of Granules India?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Jul-2024 16:01 the market cap of Granules India stood at ₹13,656.3.

What is the P/E ratio of Granules India?

The latest P/E ratio of Granules India as of 26-Jul-2024 16:01 is 31.33.

What is the P/B ratio of Granules India?

The latest P/B ratio of Granules India as of 26-Jul-2024 16:01 is 4.41.

What is the 52-week high and low of Granules India?

The 52-week high of Granules India is ₹566.5 and the 52-week low is ₹287.6.

What is the TTM revenue of Granules India?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Granules India is ₹3,755 ( Cr.) .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated Company founded in 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). The Company over the years has created a strong presence in ‘the first line of defence’ products such as Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin.

The company’s product-focused, vertically integrated business model has created a leadership position in several generic drugs. It has a strong presence in ‘first line of defence’ products, including Paracetamol, Ibuprofen, Guaifenesin and Metformin. It exports nearly 60% of its revenue to the US and Europe. Its key customers include some of the leading generic, as well as, branded pharmaceutical companies. Its integrated model for manufacturing APIs, PFIs and Finished Dosages enables it to provide products across the value chain and enhances its competitiveness. It has emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

Business area of the company

Granules India is one of the vertically integrated, high-growth pharmaceutical manufacturing company in India today. Based out of Hyderabad, India, it is into manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediaries (PFIs) and Finished Dosages (FDs).

Products of the company

Active Pharmaceutical Ingredients
Pharmaceutical Formulation Intermediates
Finished Dosages
Speciality Products

Milestones

1991: Trading of APIs
1994: Production of various APIs
1995: Venture into the manufacture of DC Paracetemol (PFI)
1996: Targeting of OTC market in the US for Paracetemol PFI.
1998: Expansion of PFI capacity.
2000: Obtaining US FDA approval for PFI and other APIs.
2001: Development of new PFIs such as Guaifenesin, Metformin and Ibuprofen etc.
2002: Filing of new DMFs of the above PFIs and moving up of value chain in OTC products.
2003: Setting up of the world's single largest PFI facility with a capacity of 7,200 TPA.
2004: The only company in the world to manufacture combination PFIs on a commercial scale using different basic APIs with other excipients.
2004: Addition of a Tableting facility with a capacity of one billion pieces per annum
2005: Started construction of the Tableting facility with a capacity of 12 billion tablets.
2006: Major expansion of Paracetamol facility, from a capacity of 3600 MT to 12000MT per annum
2010: Granuels India Receives U.S. FDA Approval for its Metformin ANDA.
2011: Granules established Granules-OmniChem, a JV with Ajinomoto OmniChem. The business focuses on the CRAMS space
2012: Granules India Awarded India’s Most Admired Company in Exports & India’s Most Admired Company in Bulk Drugs.
2012: Granules India Awarded Outstanding Exports - Formulations Award 2011-12 by Pharmexcil.
2013: Granules acquired Auctus Pharma.
2016: Wholly owned subsidiary Granules Pharmaceticals Inc (GPI) enters into agreement to acquire 12.5% stake in US based USPharma.
2017: Granules India Limited featured in the list at 60th place in Fortune India's 2017 list of The Next 500 Companies.
2018-19: Granules Pharmaceuticals Inc. launched generic Methylergonovine tablets (Methergine) in partnership with Hikma Pharmaceuticals Plc.
2018-19: Granules Pharmaceuticals Inc. successfully launched Metformin XR and Methocarbamol under its own label.
2020: Granules India gets nod to set up subsidiary in Hyderabad.
2020: Granules India gets marketing approval from US FDA for Potassium Chloride Extended Release Tablets.
2021: USFDA approves ANDA filed by Granules India’s arm for Potassium Chloride Oral Solution.